MedPath

The study of the new regimen of the AZT administration to the neonate for preventing HIV mother-to-child transmissio

Not Applicable
Conditions
HIV
Registration Number
JPRN-UMIN000008935
Lead Sponsor
ational Center for Global Health and Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

The mother rejects the agreement for this study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1)HIV transmission at 1 year and 6 month: HIV antibody detection 2)The degree of born marrow suppression: The minimum number of hemoglobin, white blood cell, neutrophile count, platelet between initial AZT administration and 1 or 2 months after completion.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath